Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
David Ritchie,Paul J Neeson,Paul J Neeson,Amit Khot,Stefan Peinert,Tsin Yee Tai,Kellie M. Tainton,Karen Chen,Mandy Shin,Dominic M. Wall,Dominic M. Wall,Dirk Hönemann,Peter Gambell,David Westerman,Javier Haurat,Jennifer A. Westwood,Jennifer A. Westwood,Andrew M. Scott,Lucy Kravets,Michael Dickinson,Joseph A. Trapani,Joseph A. Trapani,Mark J. Smyth,Mark J. Smyth,Phillip K. Darcy,Phillip K. Darcy,Michael H. Kershaw,Michael H. Kershaw,H. Miles Prince +28 more
Reads0
Chats0
TLDR
This study supports the feasibility and safety of CAR-T-cell therapy in high-risk AML, and demonstrates durable in vivo persistence of CAR T cells.About:
This article is published in Molecular Therapy.The article was published on 2013-11-01 and is currently open access. It has received 356 citations till now. The article focuses on the topics: Myeloid leukemia & Leukemia.read more
Citations
More filters
Journal ArticleDOI
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Journal ArticleDOI
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
TL;DR: The results of the reported clinical trials are reviewed and the progress and key emerging factors that may play a role in effecting tumor responses are discussed, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies.
Journal ArticleDOI
Design and development of therapies using chimeric antigen receptor-expressing T cells
TL;DR: The value of adding additional engineering features to CAR‐T cells, irrespective of their target, to render them better suited to function in the tumor environment, and the safety of these heavily modified cells may be maintained are shown.
Journal ArticleDOI
Driving CAR T-cells forward
TL;DR: This Review discusses trials and strategies that can increase the antitumour efficacy and safety of CAR T-cell therapy and only discusses studies with direct translational application currently or soon-to-be tested in the clinical setting.
Journal ArticleDOI
Gene-engineered T cells for cancer therapy
TL;DR: Using genetic modification, highly active, self-propagating 'slayers' of cancer cells can be generated.
References
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
TL;DR: A low dose of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission.
Journal ArticleDOI
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos,Bruce L. Levine,David L. Porter,Sharyn I. Katz,Stephan A. Grupp,Stephan A. Grupp,Adam Bagg,Carl H. June +7 more
TL;DR: It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL).
Journal ArticleDOI
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
Richard A. Morgan,James Chih-Hsin Yang,Mio Kitano,Mark E. Dudley,Carolyn M. Laurencot,Steven A. Rosenberg +5 more
TL;DR: It is speculated that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells, consistent with a cytokine storm.
Journal ArticleDOI
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q. Phan,James Chih-Hsin Yang,Richard M. Sherry,Patrick Hwu,Suzanne L. Topalian,Douglas J. Schwartzentruber,Nicholas P. Restifo,Leah R. Haworth,Claudia A. Seipp,Linda J. Freezer,Kathleen E. Morton,Sharon Mavroukakis,Paul H. Duray,Seth M. Steinberg,James P. Allison,Thomas A. Davis,Steven A. Rosenberg +16 more
TL;DR: This study establishes CTLA-4 as an important molecule regulating tolerance to “self” antigens in humans and suggests a role for CTla-4 blockade in breaking tolerance to human cancer antIGens for cancer immunotherapy.
Related Papers (5)
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila,Isabelle Riviere,Xiuyan Wang,Shirley Bartido,Jae H. Park,Kevin J. Curran,Stephen S. Chung,Jolanta Stefanski,Oriana Borquez-Ojeda,Malgorzata Olszewska,Jinrong Qu,Teresa Wasielewska,Qing He,Mitsu Fink,Himaly Shinglot,Maher Youssif,Mark Satter,Yongzeng Wang,James Hosey,Hilda Quintanilla,Elizabeth Halton,Yvette Bernal,Diana C. G. Bouhassira,Maria E. Arcila,Mithat Gonen,Gail J. Roboz,Peter Maslak,Dan Douer,Mark G. Frattini,Sergio Giralt,Michel Sadelain,Renier J. Brentjens +31 more
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens,Marco L. Davila,Isabelle Riviere,Jae H. Park,Xiuyan Wang,Lindsay G. Cowell,Shirley Bartido,Jolanta Stefanski,Clare Taylor,Malgorzata Olszewska,Oriana Borquez-Ojeda,Jinrong Qu,Teresa Wasielewska,Qing He,Yvette Bernal,Ivelise Rijo,Cyrus V. Hedvat,Rachel Kobos,Kevin J. Curran,Peter G. Steinherz,Joseph G. Jurcic,Todd L. Rosenblat,Peter Maslak,Mark G. Frattini,Michel Sadelain +24 more